Literature DB >> 12466191

Cellular actions of the insulin-like growth factor binding proteins.

Sue M Firth1, Robert C Baxter.   

Abstract

In addition to their roles in IGF transport, the six IGF-binding proteins (IGFBPs) regulate cell activity in various ways. By sequestering IGFs away from the type I IGF receptor, they may inhibit mitogenesis, differentiation, survival, and other IGF-stimulated events. IGFBP proteolysis can reverse this inhibition or generate IGFBP fragments with novel bioactivity. Alternatively, IGFBP interaction with cell or matrix components may concentrate IGFs near their receptor, enhancing IGF activity. IGF receptor-independent IGFBP actions are also increasingly recognized. IGFBP-1 interacts with alpha(5)beta(1) integrin, influencing cell adhesion and migration. IGFBP-2, -3, -5, and -6 have heparin-binding domains and can bind glycosaminoglycans. IGFBP-3 and -5 have carboxyl-terminal basic motifs incorporating heparin-binding and additional basic residues that interact with the cell surface and matrix, the nuclear transporter importin-beta, and other proteins. Serine/threonine kinase receptors are proposed for IGFBP-3 and -5, but their signaling functions are poorly understood. Other cell surface IGFBP-interacting proteins are uncharacterized as functional receptors. However, IGFBP-3 binds and modulates the retinoid X receptor-alpha, interacts with TGFbeta signaling through Smad proteins, and influences other signaling pathways. These interactions can modulate cell cycle and apoptosis. Because IGFBPs regulate cell functions by diverse mechanisms, manipulation of IGFBP-regulated pathways is speculated to offer therapeutic opportunities in cancer and other diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466191     DOI: 10.1210/er.2001-0033

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  527 in total

1.  Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Lei Zhao; Li-Ru He; Rui Zhang; Mu-Yan Cai; Yi-Ji Liao; Dong Qian; Mian Xi; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

Review 2.  What's new in the IGF-binding proteins?

Authors:  Steven A Rosenzweig
Journal:  Growth Horm IGF Res       Date:  2004-10       Impact factor: 2.372

Review 3.  The multi-functional role of insulin-like growth factor binding proteins in bone.

Authors:  Kristen E Govoni; David J Baylink; Subburaman Mohan
Journal:  Pediatr Nephrol       Date:  2004-11-11       Impact factor: 3.714

4.  Predicting response to growth hormone treatment.

Authors:  Leena Patel; Peter E Clayton
Journal:  Indian J Pediatr       Date:  2011-11-22       Impact factor: 1.967

Review 5.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

6.  IGFBP-3 sensitizes prostate cancer cells to interferon-gamma-induced apoptosis.

Authors:  Peng Fang; Vivian Hwa; Brian M Little; Ron G Rosenfeld
Journal:  Growth Horm IGF Res       Date:  2007-08-24       Impact factor: 2.372

7.  Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit.

Authors:  David L Hwang; Phillip D K Lee; Pinchas Cohen
Journal:  Growth Horm IGF Res       Date:  2007-08-23       Impact factor: 2.372

8.  Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study.

Authors:  Yasushi Adachi; Masanori Nojima; Mitsuru Mori; Yasutaka Matsunaga; Noriyuki Akutsu; Shigeru Sasaki; Takao Endo; Youichi Kurozawa; Kenji Wakai; Akiko Tamakoshi
Journal:  Tumour Biol       Date:  2016-09-23

9.  Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.

Authors:  Charles S Fuchs; Richard M Goldberg; Daniel J Sargent; Jeffrey A Meyerhardt; Brian M Wolpin; Erin M Green; Henry C Pitot; Michael Pollak
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

Review 10.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.